Page last updated: 2024-10-31

apnea and Cerebral Palsy

apnea has been researched along with Cerebral Palsy in 13 studies

Apnea: A transient absence of spontaneous respiration.

Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)

Research Excerpts

ExcerptRelevanceReference
" Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines."9.41Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023)
"3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004."9.16Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012)
"We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed."9.12Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007)
"Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation."8.82Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005)
"The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported."7.68Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993)
" Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines."5.41Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023)
"3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004."5.16Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012)
"We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed."5.12Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007)
"Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation."4.82Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005)
" Subjects with CP had greater variability and duration of deglutition apnea than controls."3.73The effect of viscosity on the breath-swallow pattern of young people with cerebral palsy. ( Moussavi, Z; Rempel, G, 2005)
" Perioperative complications were postanesthetic seizure and postoperative brief apnea."3.71[Anesthetic management for laryngotracheal separation and tracheoesophageal diversion]. ( Kujime, Y; Obara, H; Okada, N; Sakai, K; Shiga, M; Takekida, S, 2002)
"The neurodevelopmental outcome of premature infants with persistent apnea of prematurity (AOP) is reported."3.68Neurodevelopmental outcome of infants with apnea of infancy. ( Hegyi, T; Hiatt, M; Jadeja, N; Koons, AH; Mojica, N; Ostfeld, B, 1993)
" This study also identified a short-latency apnea that appears to accompany a saliva (protective) swallow and a long-latency apnea that accompanies semi-solid or liquid bolus (alimentary) swallows."3.67Correlation of ultrasound imaging of oral swallow with ventilatory alterations in cerebral palsied and normal children: preliminary observations. ( Casas, MJ; Kenny, DJ; McPherson, KA, 1989)
"Babies with seizures, as well as those with terminal apnoea, were also substantially more likely than controls to have been born after a failure to react appropriately to signs of severe fetal distress during labour."2.65Adverse outcome of pregnancy and the quality of obstetric care. ( Chalmers, I; Elbourne, D; Henson, G; Macfarlane, A; Niswander, K; Redman, C; Tizard, P, 1984)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19903 (23.08)18.7374
1990's2 (15.38)18.2507
2000's5 (38.46)29.6817
2010's1 (7.69)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Marques, KA1
Bruschettini, M1
Roehr, CC1
Davis, PG3
Fiander, M1
Soll, R1
Mohon, RT1
Khan, E1
DelRosso, LM1
Schmidt, B3
Anderson, PJ1
Doyle, LW3
Dewey, D1
Grunau, RE1
Asztalos, EV1
Tin, W2
Moddemann, D1
Solimano, A2
Ohlsson, A2
Barrington, KJ2
Roberts, RS2
Takekida, S1
Okada, N1
Kujime, Y1
Sakai, K1
Shiga, M1
Obara, H1
Rempel, G1
Moussavi, Z1
Davis, P1
Niswander, K1
Henson, G1
Elbourne, D1
Chalmers, I1
Redman, C1
Macfarlane, A1
Tizard, P1
Koch, B1
Braillier, D1
Eng, G1
Binder, H1
Koons, AH1
Mojica, N1
Jadeja, N1
Ostfeld, B1
Hiatt, M1
Hegyi, T1
Tamura, F1
Shishikura, J1
Mukai, Y1
Kaneko, Y1
Rickards, AL1
Kelly, EA1
Ford, GW1
Davis, NM1
Callanan, C1
Kenny, DJ1
Casas, MJ1
McPherson, KA1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312]Phase 32,000 participants (Anticipated)Interventional1999-10-31Completed
Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784]Phase 118 participants (Anticipated)Interventional2024-06-30Not yet recruiting
A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182]Phase 2/Phase 37 participants (Actual)Interventional2011-10-31Terminated (stopped due to Low recruitment rate)
Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357]Phase 3201 participants (Actual)Interventional2009-11-30Completed
[NCT01066728]Phase 2/Phase 387 participants (Actual)Interventional2001-08-31Completed
A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473]Phase 424 participants (Actual)Interventional2017-02-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for apnea and Cerebral Palsy

ArticleYear
Methylxanthine for the prevention and treatment of apnea in preterm infants.
    The Cochrane database of systematic reviews, 2023, 10-31, Volume: 10

    Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur

2023
Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
    Biology of the neonate, 2005, Volume: 88, Issue:3

    Topics: Aging; Apnea; Blindness; Cerebral Palsy; Cognition Disorders; Deafness; Follow-Up Studies; Humans; I

2005

Trials

3 trials available for apnea and Cerebral Palsy

ArticleYear
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Adverse outcome of pregnancy and the quality of obstetric care.
    Lancet (London, England), 1984, Oct-13, Volume: 2, Issue:8407

    Topics: Adolescent; Apnea; Asphyxia Neonatorum; Birth Injuries; Cerebral Palsy; Clinical Trials as Topic; En

1984

Other Studies

8 other studies available for apnea and Cerebral Palsy

ArticleYear
Increasingly Familiar Breathing Pattern in an Unfamiliar Population. Sleep-related Breathing Disorders in High-Risk Patients.
    Annals of the American Thoracic Society, 2020, Volume: 17, Issue:7

    Topics: Apnea; Baclofen; Cerebral Palsy; Child; Female; Humans; Polysomnography; Sleep; Sleep Apnea, Central

2020
[Anesthetic management for laryngotracheal separation and tracheoesophageal diversion].
    Masui. The Japanese journal of anesthesiology, 2002, Volume: 51, Issue:9

    Topics: Adolescent; Anastomosis, Surgical; Anesthesia, General; Apnea; Cerebral Palsy; Child; Child, Prescho

2002
The effect of viscosity on the breath-swallow pattern of young people with cerebral palsy.
    Dysphagia, 2005,Spring, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Analysis of Variance; Apnea; Case-Control Studies; Cerebral Palsy; Deglutition; D

2005
Computerized tomography in cerebral-palsied children.
    Developmental medicine and child neurology, 1980, Volume: 22, Issue:5

    Topics: Adolescent; Apnea; Brain; Cerebral Palsy; Child; Child, Preschool; Hemiplegia; Humans; Infant; Infan

1980
Neurodevelopmental outcome of infants with apnea of infancy.
    American journal of perinatology, 1993, Volume: 10, Issue:3

    Topics: Apnea; Cerebral Palsy; Child, Preschool; Developmental Disabilities; Female; Follow-Up Studies; Huma

1993
Arterial oxygen saturation in severely disabled people: effect of oral feeding in the sitting position.
    Dysphagia, 1999,Fall, Volume: 14, Issue:4

    Topics: Adolescent; Adult; Airway Obstruction; Apnea; Blood Circulation; Cerebral Palsy; Cough; Disabled Per

1999
Methylxanthines and sensorineural outcome at 14 years in children < 1501 g birthweight.
    Journal of paediatrics and child health, 2000, Volume: 36, Issue:1

    Topics: Adolescent; Apnea; Bronchodilator Agents; Cerebral Palsy; Child Development; Developmental Disabilit

2000
Correlation of ultrasound imaging of oral swallow with ventilatory alterations in cerebral palsied and normal children: preliminary observations.
    Dysphagia, 1989, Volume: 4, Issue:2

    Topics: Apnea; Cerebral Palsy; Deglutition; Humans; Respiration; Ultrasonography

1989